Biotech

Biotech penny stock Kalytera Therapeutics has a huge upside, says Echelon

Echelon Wealth Partners analyst Douglas Loe calls the new update from Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart, News TSXV:KLY) “highly positive”. Saying the cannabinoid-focused drug developer is likely to proceed to Phase III trials for its CBD-based drug formulation. In ...

A Mystery Group Emerges To Lead Friday's Stock Market Rally

Special Event Today Every quarter, I announce my Top 10 Stocks (equally-weighted) for my Model, Aggressive and Income portfolios. Today's the day! It all starts at 4:30pm EST. CLICK HERE for portfolio performance and registration information. Market Recap for Friday, August 16, 2019 Industrials (XL ...

New book based on 20 years providing business guidance to drug companies [Free Sample]  [Buy printed book from Amazon] [More Details] Make Better Decisions helps generic and branded companies alike find and evaluate drug market entry opportunities. Billions of dollars can change hands when key ...

Small Caps and Biotechs Have Both Turned Positive - Here Are 3 Candidates for Your Consideration

June is shaping up to be quite a month, with the S&P 500 on track to outpace January as the best-performing period. Of special note is this week’s move into Biotechnology and Small Cap stocks, which both have struggled since stalling out in February. With money flows into these laggards, a downt ...

Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements

This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) Abstract A 505(b)(2)… The post Review of Dr ...

HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, June 5, 2019 /CNW/ – HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX:HLS) is pleased to announce that it ...

Zymeworks has a 69 per cent upside, says Paradigm Capital

Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) has a new licensing agreement for its proprietary Zymelink antibody-drug conjugate (ADC) platform, an event which Paradigm Capital analyst Rahul Sarugaser says is further proof that Zymeworks’ platfor ...

Three Finalists Announced for the 2019 Bloom Burton Award

Three Finalists Announced for the 2019 Bloom Burton Award Award Recognizes the Year’s Most Significant Contributor to Canada’s Innovative Healthcare Industry TORONTO, May 6, 2019 – Bloom Burton & Co. is pleased to announce the three finalists for the 2019 Bloom Burton Award. Bestowed annually ...

Tetra Bio-Pharma is a leader in the cannabis biopharmaceutical space: Paradigm

A high need for safe and effective pain drugs in the wake of the opioid crisis shows the potential value in Tetra Bio-Pharma’s (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP) cannabinoid drug candidate, CAUMZ. That’s according to analyst Rahul Sarugaser of Paradigm Capital, who in a Thursday res ...

Zymeworks has an upside of 82 per cent, Paradigm Capital says

Paradigm Capital analyst Rahul Sarugaser says he’s spotted a consistent lag in the market’s appreciation of material developments concerning clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart NYSE:ZYME), one which makes for a great buying opportunity. In an update ...